Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Arcus Biosciences (RCUS) EBIAT (2017 - 2025)

Arcus Biosciences has reported EBIAT over the past 9 years, most recently at -$106.0 million for Q4 2025.

  • Quarterly results put EBIAT at -$106.0 million for Q4 2025, down 12.77% from a year ago — trailing twelve months through Dec 2025 was -$353.0 million (down 24.73% YoY), and the annual figure for FY2025 was -$353.0 million, down 24.73%.
  • EBIAT for Q4 2025 was -$106.0 million at Arcus Biosciences, up from -$135.0 million in the prior quarter.
  • Over the last five years, EBIAT for RCUS hit a ceiling of $279.5 million in Q4 2021 and a floor of -$135.0 million in Q3 2025.
  • Median EBIAT over the past 5 years was -$76.0 million (2021), compared with a mean of -$60.9 million.
  • Peak annual rise in EBIAT hit 639.1% in 2021, while the deepest fall reached 4379.64% in 2021.
  • Arcus Biosciences' EBIAT stood at $279.5 million in 2021, then tumbled by 123.97% to -$67.0 million in 2022, then fell by 20.9% to -$81.0 million in 2023, then dropped by 16.05% to -$94.0 million in 2024, then fell by 12.77% to -$106.0 million in 2025.
  • The last three reported values for EBIAT were -$106.0 million (Q4 2025), -$135.0 million (Q3 2025), and -$112.0 million (Q1 2025) per Business Quant data.